deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT03650491

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Sponsor: Fortis Therapeutics, Inc.

Conditions Multiple Myeloma Multiple Myeloma With Failed Remission Multiple Myeloma in Relapse
Interventions FOR46
Updated 13 times since 2018 Last updated: Jul 25, 2022 Started: Apr 3, 2019 Primary completion: Jan 31, 2022 Completion: Jan 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Multiple Myeloma and Multiple Myeloma With Failed Remission, this trial is completed. The trial is conducted by Fortis Therapeutics, Inc. and has accumulated 13 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2018 – ~Jul 2019 · 10 months · monthly snapshot~Jul 2019 – ~Jan 2020 · 6 months · monthly snapshot~Jan 2020 – ~Oct 2020 · 9 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. Mar 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 8 earlier versions

  1. Sep 2021 — Mar 2022 [monthly]

    Recruiting PHASE1

  2. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  3. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  5. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  6. Jan 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  7. Jul 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  8. Sep 2018 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fortis Therapeutics, Inc.
Data source: Fortis Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations